This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Abbott, J. D. Search for Related Content PubMed Articles by Abbott, J. D. Related Collections Catheter-based coronary interventions: stents Coronary imaging: angiography/ultrasound/Doppler/CC Related Articles

Editorials

Revealing the Silver and Red Lining in Drug-Eluting Stents With Angioscopy

J. Dawn Abbott, MD

From the Division of Cardiology, Rhode Island Hospital, Brown University, Providence, RI.

Correspondence to J. Dawn Abbott, MD, Division of Cardiology, Rhode Island Hospital, Assistant Professor, Brown Medical School, 814 APC, 593 Eddy St, Providence, RI 02903. E-mail jabbott@lifespan.org

Key Words: Editorials • imaging • stents • angioscopy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Drug-eluting stents (DES) are widely used in percutaneous coronary intervention and have resulted in significant reductions in target-vessel revascularization as compared with bare-metal stents (BMS) in randomized, controlled trials and in unrestricted patient and lesion subsets.^1,2 Comprehensive analyses have proven the safety of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) compared with BMS, with similar rates of death and myocardial infarction after as much as 4 years of follow-up^2,3; however, a valid safety concern remains, given that DES increase the risk of late (>30 days) and very late (>1 year) stent thrombosis compared with BMS. Our understanding of the risk factors for stent thrombosis has been derived from experimental models, pathological findings, and clinical trials. The mechanisms underlying the increased thrombogenicity of DES are multifactorial and include patient, lesion, and procedural factors, as well as compliance with and response to antiplatelet therapy.^4–6 However, all currently available DES may be susceptible to late and very late stent thrombosis because of the delayed arterial healing and impaired endothelialization that accompany the drugs used to inhibit neointimal hyperplasia. We can postulate that the rate of healing varies from patient to patient, and even from lesion to lesion within the same patient, but we do not have a method to assess or measure healing after stenting. Therefore, we have empirically recommended that dual-antiplatelet therapy be extended for at least 12 months after DES implantation in an effort to reduce events during the period when the stent is prone to thrombus formation.⁷

Articles see . . . [Full Text of this Article]

Related Articles

Lack of Association Between Large Angiographic Late Loss and Low Risk of In-Stent Thrombus: Angioscopic Comparison Between Paclitaxel- and Sirolimus-Eluting Stents

Masamichi Takano, Masanori Yamamoto, Daisuke Murakami, Shigenobu Inami, Kentaro Okamatsu, Koji Seimiya, Takayoshi Ohba, Yoshihiko Seino, and Kyoichi Mizuno
Circ Cardiovasc Interv 2008 1: 20-27. [Abstract] [Full Text] [PDF]

High Incidence of Intramural Thrombus After Overlapping Paclitaxel-Eluting Stent Implantation: Angioscopic and Histopathologic Analysis in Porcine Coronary Arteries

Toshiro Shinke, Jinsheng Li, Jack P. Chen, Lakshmana Pendyala, Traci Goodchild, Refat Jabara, Sarah Geva, Takafumi Ueno, Nicolas Chronos, Keith Robinson, and Dongming Hou
Circ Cardiovasc Interv 2008 1: 28-35. [Abstract] [Full Text] [PDF]